The Future Of Regulatory Operations

By Rama Mohan Rao Chikkam, Senior Director of Global Regulatory Operations and APAC RA; Marcela Miño, Senior Director of Regulatory Affairs and Drug Development and Global Head of Lifecycle Management; Keith McDonald, Head of Drug Development Strategy; and David Cameron, Senior Director and Global Group Head, Novel Trial Design Solutions

Biopharmaceutical companies seeking efficient lifecycle management for their therapeutics need a strong, adaptable regulatory strategy that accounts for a range of factors, including manufacturing, pharmacovigilance, and supply chain reliability. Whether conducting your regulatory management in-house or with an experienced regulatory services provider, it is important to stay abreast of the emerging trends across the industry so that your team can adapt accordingly.

In a recent panel discussion featuring a team of IQVIA’s regulatory and drug development strategy experts, Marcela Miño, Senior Director and Global Head of Lifecycle Management; Rama Mohan Rao Chikkam, Senior Director of Global Regulatory Operations and APAC RA; Keith McDonald, Head of Drug Development Strategy; and David Cameron, Senior Director and Global Group Head, Novel Trial Design Solutions, each highlighted the trends they see driving regulatory strategy decisions. Download the full article to learn more about global regulatory changes coming online in 2024 and 2025 as well as how companies are beginning to leverage automation to streamline their lifecycle management processes and reduce risks.